An Open-label and Single-center Phase IIa Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 DNA Vaccine (ICCOV) in Healthy Subjects Aged 18-75 Years
Latest Information Update: 08 May 2025
At a glance
- Drugs COVID-2019 DNA vaccine-Immuno Cure 3/The University of Hong Kong (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Immuno Cure
Most Recent Events
- 30 Apr 2025 Status changed from active, no longer recruiting to completed.
- 15 Feb 2024 Planned End Date changed from 31 Oct 2023 to 31 May 2024.
- 15 Feb 2024 Status changed from recruiting to active, no longer recruiting.